GlassScriptPhysician profile
Dina L Bredeau
NPI 1104931732
$2,425.98
in general payments reported to CMS, 2019-2025
20 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $432 · 2023: $688 · 2024: $553 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $519.41 | 2023-2025 | |
| Abbvie INC. | $442.25 | 2021-2025 | |
| Exact Sciences Corporation | $285.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $162.59 | 2023-2025 | Veozah |
| Axonics, INC. | $141.23 | 2022 | |
| Inspire Medical Systems, INC. | $140.68 | 2024 | Inspire |
| Myriad Women'S Health, INC. | $108.34 | 2023 | Myrisk |
| Coopersurgical, INC. | $85.15 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Aspira Women'S Health INC | $80.00 | 2023 | Ova1 |
| Hologic Sales and Service, LLC | $77.62 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Millicent US INC | $73.03 | 2024-2025 | Femring, Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $62.26 | 2021-2023 | |
| Therapeuticsmd, INC. | $62.15 | 2022 | |
| Evofem Biosciences, INC. | $40.30 | 2021-2025 | Solosec, Phexx, Phexxi |
| Agile Therapeutics, INC. | $30.63 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $28.88 | 2021-2022 | |
| Biogen, INC. | $27.37 | 2024 | Zurzuvae |
| Organon LLC | $25.99 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $19.47 | 2023 | Seglentis |
| Pfizer INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Bredeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.